Literature DB >> 34847478

Dopamine, a co-regulatory component, bridges the central nervous system and the immune system.

Mingan Li1, Lin Zhou1, Xiaohui Sun1, Yunqi Yang1, Ce Zhang1, Tian Wang2, Fenghua Fu3.   

Abstract

Dopamine (DA) is a crucial neurotransmitter that plays an important role in maintaining physiological function in human body. In the past, most studies focused on the relationship between the dopaminergic system and neurological-related diseases. However, it has been found recently that DA is an immunomodulatory mediator and many immune cells express dopamine receptors (DRs). Some immune cells can synthesize and secrete DA and then participate in regulating immune function. DRs agonists or antagonists can improve the dysfunction of immune system through classical G protein signaling pathways or other non-receptor-dependent pathways. This article will discuss the relationship between the dopaminergic system and the immune system. It will also review the use of DRs agonists or antagonists to treat chronic and acute inflammatory diseases and corresponding immunomodulatory mechanisms.
Copyright © 2021 The Authors. Published by Elsevier Masson SAS.. All rights reserved.

Entities:  

Keywords:  Agonist; Antagonist; Dopamine receptor; Immune system; Inflammation

Mesh:

Substances:

Year:  2021        PMID: 34847478     DOI: 10.1016/j.biopha.2021.112458

Source DB:  PubMed          Journal:  Biomed Pharmacother        ISSN: 0753-3322            Impact factor:   6.529


  3 in total

1.  Continuous Activation of Dopamine Receptors Alleviates LPS-Induced Liver Injury in Mice via β-arrestin2 Dependent Akt/NF-κB Pathway.

Authors:  Mingan Li; Ce Zhang; Lin Zhou; Xiaohui Sun; Tian Wang; Fenghua Fu
Journal:  Front Pharmacol       Date:  2022-03-14       Impact factor: 5.810

2.  HBM4EU Chromates Study: Urinary Metabolomics Study of Workers Exposed to Hexavalent Chromium.

Authors:  Lucyna Kozłowska; Tiina Santonen; Radu Corneliu Duca; Lode Godderis; Karolina Jagiello; Beata Janasik; An Van Nieuwenhuyse; Katrien Poels; Tomasz Puzyn; Paul T J Scheepers; Monika Sijko; Maria João Silva; Anita Sosnowska; Susana Viegas; Jelle Verdonck; Wojciech Wąsowicz
Journal:  Metabolites       Date:  2022-04-18

3.  Potential Targets and Action Mechanism of Gastrodin in the Treatment of Attention-Deficit/Hyperactivity Disorder: Bioinformatics and Network Pharmacology Analysis.

Authors:  Zhe Song; Guangzhi Luo; Chengen Han; Guangyuan Jia; Baoqing Zhang
Journal:  Evid Based Complement Alternat Med       Date:  2022-09-12       Impact factor: 2.650

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.